EU GLP-1 Agonists Market, by Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide) and by Brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138206
- Pages: 200
-
Format:
Report Overview
The EU GLP-1 Agonists market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 14.5% during the forecast period
GLP-1 receptor agonists mimic the action of endogenous GLP-1 to enhance insulin secretion and inhibit glucagon secretion from pancreatic islet cells. As a monotherapy, these agents reduce HbA1C by about 1.0% in individuals with normal kidney function, with negligible risk for hypoglycemia. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes
Europe has approximately 56.3 million adults living with diabetes, and this number is expected to reach 70 million by 2023, which would represent around 10% of the total population of Europe. Europe's expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe
Market Drivers
Factors such as, exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients. With the increase in the diabetes population, the need and demand for diabetes drugs are expected to increase. Other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market
1. EU GLP-1 Agonists Market Overview
A. Market Size
2. EU GLP-1 Agonists Market Growth Drivers
I. Exponential growth of the diabetes population
II. Increase in innovation and demand for diabetes drugs
3. EU GLP-1 Agonists Market Segmentation.
A. By Drug Class
I. Exenatide
II. Liraglutide
III. Dulaglutide
IV. Lixisenatide
B. By Brand
I. Byetta
II. Bydureon
III. Victoza
IV. Trulicity
V. Lyxumia
4. EU GLP-1 Agonists Market Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Novo Nordisk Company overview, Product & Services, Strategies & Financials
B. Astra Zeneca Pharmaceuticals Company overview, Product & Services, Strategies & Financials
C. Eli Lilly Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Market Opportunities and Future Trends
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
